BeiGene Stomach-Cancer Treatment Gets FDA Approval, Second in U.S.

Dow Jones2024-12-27

By Denny Jacob

BeiGene said U.S. regulators had approved its Tevimbra to treat a form of stomach cancer.

The oncology company said the Food and Drug Administration approved Tevimbra in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment for advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.

"This is the second U.S. approval for Tevimbra this year, underscoring its potential to address critical needs in oncology," Chief Medical Officer Mark Lanasa said.

BeiGene said the approval was based on results from a global Phase 3 trial that evaluated the efficacy and safety of Tevimbra in combination with chemotherapy as a first-line treatment for adults with the disease. The company added the study met its primary endpoint and demonstrated a statistically significant and clinically meaningful overall survival benefit.

Tevimbra is also approved in the U.S. as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that doesn't include a PD-(L)1 inhibitor.

BeiGene added that it intends to change its name to BeOne Medicines.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

December 27, 2024 06:29 ET (11:29 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2494972806?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-27 19:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494972806","market":"us","top_or_hot":-1,"title":"BeiGene Stomach-Cancer Treatment Gets FDA Approval, Second in U.S.","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  BeiGene said U.S. regulators had approved its Tevimbra to treat a form of stomach cancer. \n</p>\n<p>\n  The oncology company said the Food and Drug Administration approved Tevimbra in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment for advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. \n</p>\n<p>\n  \"This is the second U.S. approval for Tevimbra this year, underscoring its potential to address critical needs in oncology,\" Chief Medical Officer Mark Lanasa said. \n</p>\n<p>\n  BeiGene said the approval was based on results from a global Phase 3 trial that evaluated the efficacy and safety of Tevimbra in combination with chemotherapy as a first-line treatment for adults with the disease. The company added the study met its primary endpoint and demonstrated a statistically significant and clinically meaningful overall survival benefit. \n</p>\n<p>\n  Tevimbra is also approved in the U.S. as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that doesn't include a PD-(L)1 inhibitor. \n</p>\n<p>\n  BeiGene added that it intends to change its name to BeOne Medicines. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 27, 2024 06:29 ET (11:29 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene Stomach-Cancer Treatment Gets FDA Approval, Second in U.S.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene Stomach-Cancer Treatment Gets FDA Approval, Second in U.S.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-27 19:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Denny Jacob \n\n\n \n\n\n  BeiGene said U.S. regulators had approved its Tevimbra to treat a form of stomach cancer. \n\n\n  The oncology company said the Food and Drug Administration approved Tevimbra in ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4107","symbol_name":"财产与意外伤害保险","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2494972806","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494972806","pubTimestamp":1735298940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BeiGene said U.S. regulators had approved its Tevimbra to treat a form of stomach cancer.The oncology company said the Food and Drug Administration approved Tevimbra in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment for advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.\"This is the second U.S. approval for Tevimbra this year, underscoring its potential to address critical needs in oncology,\" Chief Medical Officer Mark Lanasa said.BeiGene said the approval was based on results from a global Phase 3 trial that evaluated the efficacy and safety of Tevimbra in combination with chemotherapy as a first-line treatment for adults with the disease. The company added the study met its primary endpoint and demonstrated a statistically significant and clinically meaningful overall survival benefit.Tevimbra is also approved in the U.S. as monotherapy for the treatment of adult patients with unresecta","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4107":"财产与意外伤害保险","BGNE":"百济神州","06160":"百济神州","L":"洛斯公司","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"百济神州胃癌治疗获得FDA批准，在美国排名第二。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1,"BGNE":1,"L":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  BeiGene said U.S. regulators had approved its Tevimbra to treat a form of stomach cancer. \n\n\n  The oncology company said the Food and Drug Administration approved Tevimbra in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment for advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. \n\n\n  \"This is the second U.S. approval for Tevimbra this year, underscoring its potential to address critical needs in oncology,\" Chief Medical Officer Mark Lanasa said. \n\n\n  BeiGene said the approval was based on results from a global Phase 3 trial that evaluated the efficacy and safety of Tevimbra in combination with chemotherapy as a first-line treatment for adults with the disease. The company added the study met its primary endpoint and demonstrated a statistically significant and clinically meaningful overall survival benefit. \n\n\n  Tevimbra is also approved in the U.S. as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that doesn't include a PD-(L)1 inhibitor. \n\n\n  BeiGene added that it intends to change its name to BeOne Medicines. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 27, 2024 06:29 ET (11:29 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2494972806"}